Kfar Saba, Israel

Meital Sooliman


Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovative Approaches in Dementia Treatment: The Contributions of Meital Sooliman

Introduction: Meital Sooliman, an accomplished inventor based in Kfar Saba, Israel, has made significant strides in the realm of medical research. With a focus on immune therapy for dementia treatment, her work is paving the way for innovative solutions to this challenging ailment.

Latest Patents: Meital holds a notable patent that addresses methods and compositions involving immune therapy for the treatment of dementia. This patent details novel antibodies and methodologies that aim to ameliorate the effects of diseases through the blocking of Amyloid Precursor Protein (APP) cleavage, a critical factor in the progression of dementia.

Career Highlights: Currently, Meital Sooliman is associated with Ramot at Tel-Aviv University Ltd., a leading research institution that emphasizes technological advancements and knowledge transfer. Through her tenure, she has significantly contributed to the research landscape, positioning herself as a key figure in medical innovation.

Collaborations: Meital has had the opportunity to collaborate with talented colleagues, including Sarit Samira and Nurit Rachamim. Together, they strive to explore groundbreaking methodologies that could redefine treatment paradigms for dementia and similar conditions.

Conclusion: As a pioneering inventor, Meital Sooliman's contributions to the field of immune therapy cannot be overlooked. Her patent on innovative treatment methods showcases her dedication to combating dementia, a condition affecting millions worldwide. Through her endeavors at Ramot at Tel-Aviv University Ltd. and collaborations with esteemed colleagues, she embodies the spirit of innovation that drives progress in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…